Article Text
Statistics from Altmetric.com
We have read with great interest the article from Deng and colleagues1 reporting on the results of a randomised, controlled clinical trial of allogeneic umbilical cord-derived mesenchymal stem cells (UC-MSCs) for lupus nephritis. The study demonstrated that the administration of intravenous UC-MSCs does not provide additional benefit to conventional immunosuppression.
Over the last decade, increasing evidence has indicated that UC-MSCs are multipotent cells with promising applications to regenerative medicine2 and also a powerful tool to modulate the immune system. UC-MSCs can interact with most immune cell types via both cell–cell contact and secretion …
Footnotes
Contributors All authors drafted and approved the letter.
Competing interests None declared.
Provenance and peer review Not commissioned; internally peer reviewed.